156:, Choueiri completed shifts with the COVID-19 service team, treating oncology patients who have either been diagnosed COVID-19 positive, or who are suspected of being COVID-19 positive. In an effort to combat COVID, he co-lead a multinational study to identify risk factors unique to cancer patients. He also continued his research into kidney cancer and developed, with Matthew Freedman, one of the first liquid biopsy methods which could detect early stages of kidney cancers with high accuracy. The test was nearly 100 per cent accurate when used with blood samples to distinguish patients with kidney cancer from those without. Similarly, Choueiri also collaborated with
161:
superior to sunitinib, which led to its FDA approval in
January 2021. He also co-led with Robert Motzer the development of the combination of Lenvatinib+pembrolizumab which was FDA approved in August 2021. Later that year, Choueiri presented during the plenary session of the ASCO meeting the results of KEYNOTE-564 trial that showed for the first time that immunotherapy can be efficacious in the adjuvant setting in high-risk renal cancer, culminating in the FDA approval of pembrolizumab in RCC after surgery. As a result of his research, Choueiri was inducted in the 2021 Giants of Cancer Care class.
136:
received ADT compared with those who didn't but could not rule out that ADT might elevate the risk of fatal heart attacks. The following year, Choueiri found that three new cancer drugs were linked to a slightly elevated chance of fatal side effects. From 2015 and for the next several years, Choueiri led the development of cabozantinib in metastatic RCC from early phase 1 to randomized trials leading to its approval in TKI-refractory disease in 2016 and in untreated RCC patients in 2017. Choueiri also co-established the
International metastatic database Consortium with
31:
240:
Miao, D.; Margolis, C. A.; Gao, W.; Voss, M. H.; Li, W.; Martini, D. J.; Norton, C.; Bossé, D.; Wankowicz, S. M.; Cullen, D.; Horak, C.; Wind-Rotolo, M.; Tracy, A.; Giannakis, M.; Hodi, F. S.; Drake, C. G.; Ball, M. W.; Allaf, M. E.; Snyder, A.; Hellmann, M. D.; Ho, T.; Motzer, R. J.; Signoretti, S.;
186:
Motzer, R. J.; Robbins, P. B.; Powles, T.; Albiges, L.; Haanen, J. B.; Larkin, J.; Mu, X. J.; Ching, K. A.; Uemura, M.; Pal, S. K.; Alekseev, B.; Gravis, G.; Campbell, M. T.; Penkov, K.; Lee, J. L.; Hariharan, S.; Wang, X.; Zhang, W.; Wang, J.; Chudnovsky, A.; Di Pietro, A.; Donahue, A. C.; Choueiri,
148:
of
Medicine at Harvard Medical School and continued in his position as the Director of the Lank Center for Genitourinary Oncology. In this role, he led the development of the combination of axitinib+avelumab from phase I to late stage trials, leading to the combination being approved for RCC therapy
135:
Choueiri collaborated with Paul Nguyen in 2011 to perform a meta-analysis of randomized studies involving 4,141 prostate cancer patients to conclude whether men receiving ADT had a higher rate of cardiovascular deaths. The conclusion of the study found that there was no difference between those who
160:
in translational and clinical research, including recently around HIF2 inhibitors in clear-cell renal cancer, where he reported on activity and safety of MK-6482 in highly-refractory RCC patients. He also led the cabozantinib+nivolumab phase 3 study (Checkmate 9ER) that showed this regimen to be
509:
Ko, J. J.; Xie, W.; Kroeger, N.; Lee, J. L.; Rini, B. I.; Knox, J. J.; Bjarnason, G. A.; Srinivas, S.; Pal, S. K.; Yuasa, T.; Smoragiewicz, M.; Donskov, F.; Kanesvaran, R.; Wood, L.; Ernst, D. S.; Agarwal, N.; Vaishampayan, U. N.; Rha, S. Y.; Choueiri, T. K.; Heng, D. Y. (March 2015).
103:. His work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic factors in advanced renal cell carcinoma (RCC). Choueiri also co-established the International metastatic database Consortium with
143:
In 2017, Choueiri led a study which found that patients with metastatic papillary renal cell carcinoma benefited from savolitinib, a drug targeted to an abnormal genetic pathway causing cancerous growth. The following year, Choueiri was appointed
512:"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study"
913:
686:
460:"Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial"
891:
817:
790:
328:
661:
353:
988:
738:
379:
107:. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.
556:
1057:
1052:
1022:
765:
1042:
914:"FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery"
411:
153:
189:"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial"
712:
613:"Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)"
124:
100:
80:
299:
1062:
582:
1047:
464:
95:
is a
Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at
169:
Choueiri and his wife Sue have two children together and are soccer fans of the MLS, Bundesliga, and
Premier League.
123:'s Faculty of Medicine. He trained at the Cleveland Clinic in Ohio after his medical school and moved in 2007 to the
120:
61:
1037:
96:
254:
243:"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma"
970:
873:
632:
157:
137:
104:
612:
962:
865:
531:
491:
440:
280:
222:
952:
855:
624:
523:
481:
473:
430:
420:
270:
262:
212:
202:
65:
193:
1013:
258:
1017:
917:
486:
459:
435:
406:
307:
275:
242:
217:
188:
145:
527:
1031:
974:
877:
769:
687:"Multinational study identifies high risk to cancer patients diagnosed with COVID-19"
636:
628:
662:"Hometown Heroes: Dr. Toni Choueiri, Revs Season Member, fighting on the frontlines"
844:"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma"
818:"CheckMate 9ER Trial Shows Benefit of Novel Doublet for Advanced Kidney Cancer"
892:"FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma"
207:
477:
791:"FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma"
511:
266:
966:
869:
739:"Nobel Prize Research Was a Winning Formula for Patient with Kidney Cancer"
535:
495:
444:
284:
226:
957:
940:
860:
843:
425:
405:
Choueiri, Toni K.; Escudier, Bernard; Powles, Thomas (November 5, 2015).
241:
Kaelin Jr, W. G.; Choueiri, T. K.; Van Allen, E. M. (February 16, 2018).
766:"Harvard Nobel Prize winner's research extends life of cancer patient"
30:
116:
989:"Giants of Cancer Care® Announces Ninth Annual Class of Inductees"
941:"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma"
99:
and
Director of the Lank Center for Genitourinary Oncology at the
713:"Biomarker test highly accurate in detecting early kidney cancer"
407:"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma"
354:"New study reassures on heart risks of prostate cancer treatment"
380:"Three 'targeted' cancer drugs raise risk of fatal side effects"
300:"Dana-Farber Oncologist Gears Up for First Pan-Mass Challenge"
557:"Targeted drug shows promise in rare advanced kidney cancer"
119:, Lebanon where he remained for his medical degree at
76:
71:
56:
51:
37:
21:
939:Choueiri, Toni K.; et al. (August 19, 2021).
842:Motzer, Robert; et al. (April 8, 2021).
8:
655:
653:
18:
956:
859:
583:"2018-2019 Recently Appointed Professors"
485:
434:
424:
274:
216:
206:
458:Choueiri, Toni K. (February 20, 2017).
333:physiciandirectory.brighamandwomens.org
178:
816:Goodman, Alice (September 19, 2020).
764:Onyeneho, Laura (December 14, 2019).
7:
945:The New England Journal of Medicine
848:The New England Journal of Medicine
412:The New England Journal of Medicine
611:Choueiri, Toni K. (May 20, 2019).
154:COVID-19 pandemic in North America
14:
991:. PR Newswire. September 16, 2021
660:Lemieux, Jeff (April 24, 2020).
629:10.1200/JCO.2019.37.15_suppl.101
115:Choueiri was born and raised in
29:
1058:Harvard Medical School faculty
1053:Saint Joseph University alumni
298:Wisnia, Saul (July 25, 2018).
1:
528:10.1016/S1470-2045(14)71222-7
1043:Lebanese medical researchers
617:Journal of Clinical Oncology
465:Journal of Clinical Oncology
125:Dana–Farber Cancer Institute
101:Dana–Farber Cancer Institute
81:Dana–Farber Cancer Institute
16:American medical oncologist
1079:
208:10.1038/s41591-020-1044-8
86:
47:
28:
1016:publications indexed by
478:10.1200/JCO.2016.70.7398
111:Early life and education
267:10.1126/science.aan5951
187:T. K. (November 2020).
121:Saint Joseph University
62:Saint Joseph University
1063:Scientists from Beirut
894:. FDA. August 11, 2021
329:"Toni K. Choueiri, MD"
97:Harvard Medical School
64:Residency/Fellowship,
958:10.1056/NEJMoa2106391
861:10.1056/NEJMoa2035716
426:10.1056/NEJMoa1510016
1048:American oncologists
666:revolutionsoccer.net
516:The Lancet Oncology
259:2018Sci...359..801M
52:Academic background
797:. January 22, 2021
590:fa.hms.harvard.edu
386:. February 6, 2012
360:. December 6, 2011
158:William Kaelin Jr.
920:November 18, 2021
854:(14): 1289–1300.
745:. January 7, 2020
419:(19): 1814–1823.
253:(6377): 801–806.
201:(11): 1733–1741.
90:
89:
1070:
1001:
1000:
998:
996:
985:
979:
978:
960:
936:
930:
929:
927:
925:
910:
904:
903:
901:
899:
888:
882:
881:
863:
839:
833:
832:
830:
828:
813:
807:
806:
804:
802:
787:
781:
780:
778:
776:
761:
755:
754:
752:
750:
735:
729:
728:
726:
724:
709:
703:
702:
700:
698:
683:
677:
676:
674:
672:
657:
648:
647:
645:
643:
608:
602:
601:
599:
597:
587:
579:
573:
572:
570:
568:
553:
547:
546:
544:
542:
506:
500:
499:
489:
455:
449:
448:
438:
428:
402:
396:
395:
393:
391:
376:
370:
369:
367:
365:
350:
344:
343:
341:
339:
325:
319:
318:
316:
314:
295:
289:
288:
278:
237:
231:
230:
220:
210:
183:
93:Toni K. Choueiri
66:Cleveland Clinic
33:
19:
1078:
1077:
1073:
1072:
1071:
1069:
1068:
1067:
1028:
1027:
1010:
1005:
1004:
994:
992:
987:
986:
982:
938:
937:
933:
923:
921:
918:Merck & Co.
912:
911:
907:
897:
895:
890:
889:
885:
841:
840:
836:
826:
824:
815:
814:
810:
800:
798:
789:
788:
784:
774:
772:
763:
762:
758:
748:
746:
743:dana-farber.org
737:
736:
732:
722:
720:
719:. June 22, 2020
711:
710:
706:
696:
694:
691:dana-farber.org
685:
684:
680:
670:
668:
659:
658:
651:
641:
639:
610:
609:
605:
595:
593:
585:
581:
580:
576:
566:
564:
563:. June 23, 2017
561:dana-farber.org
555:
554:
550:
540:
538:
508:
507:
503:
457:
456:
452:
404:
403:
399:
389:
387:
384:dana-farber.org
378:
377:
373:
363:
361:
358:dana-farber.org
352:
351:
347:
337:
335:
327:
326:
322:
312:
310:
297:
296:
292:
239:
238:
234:
194:Nature Medicine
185:
184:
180:
175:
167:
133:
113:
43:
42:Beirut, Lebanon
24:
17:
12:
11:
5:
1076:
1074:
1066:
1065:
1060:
1055:
1050:
1045:
1040:
1030:
1029:
1026:
1025:
1020:
1018:Google Scholar
1009:
1008:External links
1006:
1003:
1002:
980:
951:(8): 683–694.
931:
905:
883:
834:
808:
782:
756:
730:
704:
693:. May 28, 2020
678:
649:
603:
574:
548:
522:(3): 293–300.
501:
472:(6): 591–597.
450:
397:
371:
345:
320:
308:The Jimmy Fund
290:
232:
177:
176:
174:
171:
166:
163:
146:Full professor
132:
129:
112:
109:
88:
87:
84:
83:
78:
74:
73:
69:
68:
58:
54:
53:
49:
48:
45:
44:
41:
39:
35:
34:
26:
25:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1075:
1064:
1061:
1059:
1056:
1054:
1051:
1049:
1046:
1044:
1041:
1039:
1038:Living people
1036:
1035:
1033:
1024:
1021:
1019:
1015:
1014:Toni Choueiri
1012:
1011:
1007:
990:
984:
981:
976:
972:
968:
964:
959:
954:
950:
946:
942:
935:
932:
919:
915:
909:
906:
893:
887:
884:
879:
875:
871:
867:
862:
857:
853:
849:
845:
838:
835:
823:
819:
812:
809:
796:
792:
786:
783:
771:
770:Boston Herald
767:
760:
757:
744:
740:
734:
731:
718:
714:
708:
705:
692:
688:
682:
679:
667:
663:
656:
654:
650:
638:
634:
630:
626:
622:
618:
614:
607:
604:
591:
584:
578:
575:
562:
558:
552:
549:
537:
533:
529:
525:
521:
517:
513:
505:
502:
497:
493:
488:
483:
479:
475:
471:
467:
466:
461:
454:
451:
446:
442:
437:
432:
427:
422:
418:
414:
413:
408:
401:
398:
385:
381:
375:
372:
359:
355:
349:
346:
334:
330:
324:
321:
309:
305:
304:jimmyfund.org
301:
294:
291:
286:
282:
277:
272:
268:
264:
260:
256:
252:
248:
244:
236:
233:
228:
224:
219:
214:
209:
204:
200:
196:
195:
190:
182:
179:
172:
170:
165:Personal life
164:
162:
159:
155:
150:
149:in May 2019.
147:
141:
139:
130:
128:
126:
122:
118:
110:
108:
106:
102:
98:
94:
85:
82:
79:
75:
72:Academic work
70:
67:
63:
59:
55:
50:
46:
40:
36:
32:
27:
23:Toni Choueiri
20:
993:. Retrieved
983:
948:
944:
934:
922:. Retrieved
908:
896:. Retrieved
886:
851:
847:
837:
825:. Retrieved
822:ascopost.com
821:
811:
799:. Retrieved
794:
785:
775:December 21,
773:. Retrieved
759:
749:December 21,
747:. Retrieved
742:
733:
723:December 18,
721:. Retrieved
717:newswise.com
716:
707:
697:December 18,
695:. Retrieved
690:
681:
671:December 18,
669:. Retrieved
665:
642:December 21,
640:. Retrieved
620:
616:
606:
596:December 18,
594:. Retrieved
589:
577:
567:December 18,
565:. Retrieved
560:
551:
541:December 21,
539:. Retrieved
519:
515:
504:
469:
463:
453:
416:
410:
400:
390:December 18,
388:. Retrieved
383:
374:
364:December 18,
362:. Retrieved
357:
348:
338:December 18,
336:. Retrieved
332:
323:
313:December 18,
311:. Retrieved
303:
293:
250:
246:
235:
198:
192:
181:
168:
151:
142:
134:
114:
92:
91:
77:Institutions
827:January 29,
801:January 29,
623:(15): 101.
152:During the
138:Daniel Heng
105:Daniel Heng
1032:Categories
995:January 2,
924:January 2,
898:January 2,
173:References
975:237215136
878:231988072
637:190871839
57:Education
967:34407342
870:33616314
536:25681967
496:28199818
445:26406150
285:29301960
227:32895571
795:fda.gov
487:5455807
436:5024539
276:6035749
255:Bibcode
247:Science
218:8493486
973:
965:
876:
868:
635:
592:. 2018
534:
494:
484:
443:
433:
283:
273:
225:
215:
131:Career
117:Beirut
971:S2CID
874:S2CID
633:S2CID
586:(PDF)
997:2021
963:PMID
926:2021
900:2022
866:PMID
829:2021
803:2021
777:2020
751:2020
725:2020
699:2020
673:2020
644:2020
598:2020
569:2020
543:2020
532:PMID
492:PMID
441:PMID
392:2020
366:2020
340:2020
315:2020
281:PMID
223:PMID
60:MD,
38:Born
953:doi
949:385
856:doi
852:384
625:doi
524:doi
482:PMC
474:doi
431:PMC
421:doi
417:373
271:PMC
263:doi
251:359
213:PMC
203:doi
1034::
1023:CV
969:.
961:.
947:.
943:.
916:.
872:.
864:.
850:.
846:.
820:.
793:.
768:.
741:.
715:.
689:.
664:.
652:^
631:.
621:37
619:.
615:.
588:.
559:.
530:.
520:16
518:.
514:.
490:.
480:.
470:35
468:.
462:.
439:.
429:.
415:.
409:.
382:.
356:.
331:.
306:.
302:.
279:.
269:.
261:.
249:.
245:.
221:.
211:.
199:26
197:.
191:.
140:.
127:.
999:.
977:.
955::
928:.
902:.
880:.
858::
831:.
805:.
779:.
753:.
727:.
701:.
675:.
646:.
627::
600:.
571:.
545:.
526::
498:.
476::
447:.
423::
394:.
368:.
342:.
317:.
287:.
265::
257::
229:.
205::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
